Document is current
Any future updates will be listed below
-
Authors
Harms, Michael P. https://orcid.org/0000-0001-7945-036X
Cho, Kang-Ik K. https://orcid.org/0000-0001-7135-3848
Anticevic, Alan
Bolo, Nicolas R. https://orcid.org/0000-0002-9941-622X
Bouix, Sylvain https://orcid.org/0000-0003-1326-6054
Campbell, Dylan https://orcid.org/0009-0008-5414-2801
Cannon, Tyrone D.
Cecchi, Guillermo https://orcid.org/0000-0003-1013-8348
Goncalves, Mathias
Haidar, Anastasia
Hughes, Dylan E. https://orcid.org/0009-0003-3759-2417
Izyurov, Igor
John, Omar https://orcid.org/0009-0008-3745-7270
Kapur, Tina
Kim, Nicholas
Kotler, Elana
Kubicki, Marek https://orcid.org/0000-0002-3989-8212
Kuperman, Joshua M.
Laulette, Kristen
Lindberg, Ulrich https://orcid.org/0000-0002-0004-6354
Markiewicz, Christopher
Ning, Lipeng
Poldrack, Russell A.
Rathi, Yogesh
Romo, Paul A. III
Tamayo, Zailyn
Wannan, Cassandra https://orcid.org/0000-0003-1317-4635
Wickham, Alana
Yassin, Walid https://orcid.org/0000-0001-9612-0485
Zhou, Juan Helen https://orcid.org/0000-0002-0180-8648
Addington, Jean https://orcid.org/0000-0002-8298-0756
Alameda, Luis https://orcid.org/0000-0002-8621-2885
Arango, Celso https://orcid.org/0000-0003-3382-4754
Breitborde, Nicholas J. K.
Broome, Matthew R. https://orcid.org/0000-0002-6963-8884
Cadenhead, Kristin S. https://orcid.org/0000-0002-5952-4605
Calkins, Monica E.
Chen, Eric Yu Hai https://orcid.org/0000-0002-5247-3593
Choi, Jimmy
Conus, Philippe
Corcoran, Cheryl M. https://orcid.org/0000-0002-8902-4353
Cornblatt, Barbara A.
Diaz-Caneja, Covadonga M. https://orcid.org/0000-0001-8538-3175
Ellman, Lauren M.
Fusar-Poli, Paolo
Gaspar, Pablo A. https://orcid.org/0000-0002-9682-5327
Gerber, Carla
Glenthøj, Louise Birkedal
Horton, Leslie E.
Hui, Christy Lai Ming
Kambeitz, Joseph https://orcid.org/0000-0002-8988-3959
Kambeitz-Ilankovic, Lana
Keshavan, Matcheri S.
Kim, Sung-Wan https://orcid.org/0000-0002-6739-2163
Koutsouleris, Nikolaos https://orcid.org/0000-0001-6825-6262
Kwon, Jun Soo https://orcid.org/0000-0002-1060-1462
Langbein, Kerstin
Mamah, Daniel https://orcid.org/0000-0001-6090-4974
Mathalon, Daniel H.
Mittal, Vijay A. https://orcid.org/0000-0001-9017-5119
Nordentoft, Merete
Pearlson, Godfrey D.
Perez, Jesus
Perkins, Diana O. https://orcid.org/0000-0001-9396-2206
Powers, Albert R. III https://orcid.org/0000-0003-3057-5043
Rogers, Jack
Sabb, Fred W.
Schiffman, Jason
Shah, Jai L. https://orcid.org/0000-0002-7549-6990
Silverstein, Steven M. https://orcid.org/0000-0002-0699-0960
Smesny, Stefan
Stone, William S. https://orcid.org/0000-0003-2932-7288
Strauss, Gregory P.
Thompson, Judy L.
Upthegrove, Rachel https://orcid.org/0000-0001-8204-5103
Verma, Swapna K.
Wang, Jijun https://orcid.org/0000-0001-5427-7425
Wolf, Daniel H. https://orcid.org/0000-0002-9731-8781
Kahn, Rene S. https://orcid.org/0000-0001-5909-8004
Kane, John M.
McGorry, Patrick D.
Nelson, Barnaby
Woods, Scott W. https://orcid.org/0000-0002-3103-5228
Shenton, Martha E. https://orcid.org/0000-0003-4235-7879
Wood, Stephen J. https://orcid.org/0000-0003-4186-5919
Bearden, Carrie E. https://orcid.org/0000-0002-8516-923X
,
Pasternak, Ofer
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U24MH124629, U01MH124631, U01MH124639)
Wellcome Trust (220664/Z/20/Z, 220664/A/20/Z)
- License Information
-
More Information
Article History
Received: 2 September 2024
Accepted: 24 January 2025
First Online: 2 April 2025
Competing interests
: The authors declare the following competing interests: AA is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc.; and is a coinventor on the following patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for NeuroBehavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019; CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda; EYHC has received speaker fees at non-promotional educational events; CMD has received honoraria or travel support from Angelini, Janssen, and Viatris; PF has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Proxymm Science, and Otsuka; JK has received speaking or consulting fees from Janssen, Boehringer Ingelheim, ROVI, and Lundbeck; JMK is a consultant to or receives honoraria and/or travel support and/or speakers fees from Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Myers Squibb, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, and Teva; and is on Advisory Boards for Alkermes, Boehringer-Ingelheim, Cerevel, Click Therapeutics, Karuna/BMS, Lundbeck, Merck, Newron, Novartis, Otsuka, Sumitomo, Teva, and Terran; and has received grant support from Lundbeck, Janssen, Otsuka, and Sunovion; and has shareholder interest in Cerevel (public/stock), HealthRhythms (private/stock options), Karuna/BMS (public), LB Pharmaceuticals (private/stock options), North Shore Therapeutics (private/stock), and Vanguard Research Group (private/40% owner); RSK provides consulting to Alkermes and Boehringer-Ingelheim; PJM has been a consultant for Otsuka and TEVA; DOP is a consultant to Alkermes; ZT is a consultant for Manifest Technologies; RU has received speaker fees at non promotional educational events for Otsuka; and is a consultant for Viatris and Springer Healthcare; and is Honorary General Secretary of the British Association for Psychopharmacology (unpaid); SWW has received speaking fees from the American Psychiatric Association and from Medscape Features; and has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists; and owns stock in NW PharmaTech; All other authors report no competing interests; CMC is an Associate Editor of Schizophrenia.
